More articles from Therapeutic Agents: Biological

Abstract LB-C08: Imipridone ONC212 induces apoptosis, suppresses autophagy and synergizes upon GRP132 knockdown or exposure to lactic acid in preclinical studies of the pancreatic cancer microenvironment
Isacco Ferrarini, Aakash Jhaveri, Young Lee, Howard Safran, Lanlan Zhou, Wafik S El-Deiry

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) LB-C08; DOI: 10.1158/1535-7163.TARG-19-LB-C08
Abstract CN07-02: Immunotoxins targeting GPC3 for liver cancer
Mitchell Ho, Bryan D Fleming, Tim F Greten, Ira Pastan

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) CN07-02; DOI: 10.1158/1535-7163.TARG-19-CN07-02
Abstract LB-C07: Preclinical evaluation of MCLA-129: A bispecific antibody targeting c-MET and EGFR
Cecile Geuijen, Mario di Matteo, Tristan Gallenne, Sarah Trusso Cafarello, Roy Nijhuis, Therese Visser, Willem Bartelink, Carina Bartelink-Clements, Berina Eppink, Rinse Klooster, John dekruif, Massimiliano Mazzone, Mark Throsby

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) LB-C07; DOI: 10.1158/1535-7163.TARG-19-LB-C07
Abstract CN01-02: Maximizing the potential of bispecific antibodies for cancer drug development
Paul W H I Parren

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) CN01-02; DOI: 10.1158/1535-7163.TARG-19-CN01-02
Abstract C033: HPN328: An anti-DLL3 T cell engager for treatment of small cell lung cancer
Wade H Aaron, Richard Austin, Manasi Barath, Evan Callihan, Michael Cremin, Thomas Evans, Maria Gamez, Vaishnavi Ganti, Golzar Hemmati, Kathryn Kwant, Che-Leung Law, Bryan Lemon, Llewelyn Lao, Mary Ellen Molloy, Jessica O’Rear, Laura Sun, Holger Wesche, Stephen Yu, Timothy Yu

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C033; DOI: 10.1158/1535-7163.TARG-19-C033
Abstract C025: HexaBody-DR5/DR5 (GEN1029) shows potent preclinical antitumor activity in a variety of patient-derived xenograft (PDX) tumor models
Marije B Overdijk, Michael Cecchini, Kristin Strumane, Marcel Brandhorst, Andreas Lingnau, Paul W.H.I. Parren, Merete Ellekilde-Pedersen, Ulf Forssmann, Tahamtan Ahmadi, A. Kate Sasser, Janine Schuurman, Esther C.W. Breij, Patricia LoRusso

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C025; DOI: 10.1158/1535-7163.TARG-19-C025
Abstract C024: Ribitol enhances O-mannosylation of α-DG in breast cancer cells
qi L Lu, Pei J Lu, Jason D Tucker, Elizabeth K Branch, Fei Guo, Anthony R Blaeser

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C024; DOI: 10.1158/1535-7163.TARG-19-C024
Abstract C030: A new low potency DNA guanine monoalkylating ADC payload with enhanced in vivo tolerability
Nicolas Veillard, Paolo Andriollo, Francesco Cascio, Paul J. M. Jackson, David E. Thurston

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C030; DOI: 10.1158/1535-7163.TARG-19-C030
Abstract C023: IKS01, a next generation antibody drug conjugate, shows target-dependent efficacy in a platinum-resistant tumor model with low levels of folate receptor α expression
Jenny Thirlway, Adam Lodge, Andria Pelava, Daniel J Williamson, Davide Carta, Majid Al Nakeeb, Justyna Mysliwy, Paul J.M. Jackson, David E Thurston, Robert J Lutz

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C023; DOI: 10.1158/1535-7163.TARG-19-C023
Abstract C028: Discovery and characterization of next generation monoclonal antibodies targeting the inhibitory Fc gamma receptor CD32b for the treatment of B and plasma cell malignancies
Haihui Lu, Dongshu Chen, Sunyoung Jang, Babette Wolf, Stefan Ewert, Meghan Flaherty, Fangmin Xu, Sinan Isim, Yeonjiu Shim, Christina Dornelas, Nicole Balke, Xavier Charles Leber, Meike Scharenberg, Johanna Koelln, Eugene Choi, Rebecca Ward, Jennifer Johnson, Thomas Calzascia, Isabelle Isnardi, Juliet Williams, Heather Huet, Emma Lees, Matthew J Meyer

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C028; DOI: 10.1158/1535-7163.TARG-19-C028

Main menu

User menu

Search

More articles from Therapeutic Agents: Biological

Pages

Articles

Info for

About MCT